Regular Liver Cancer Screening for People With Cirrhosis in Central Denmark
Tests ultrasound and a blood test to catch liver cancer early in cirrhosis.
Plain-language title generated from the registry record
Registry title: Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
Key facts
- Where
- Aarhus, Herning, Horsens, Randers, Silkeborg, and Viborg, DenmarkSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 79 years old?
Source: NCT07469319, who can take part
Where in Denmark
- Aarhus University HospitalAarhus, DenmarkTaking people
- Regional Hospital GødstrupHerning, DenmarkTaking people
- Horsens Regional HospitalHorsens, DenmarkTaking people
- Randers Regional HospitalRanders, DenmarkTaking people
- Silkeborg Regional HospitalSilkeborg, DenmarkTaking people
- Viborg Regional HospitalViborg, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT07469319
- Record updated
- 13 March 2026
- Original description
This study aims to investigate whether repeated 6-monthly screening for hepatocellular carcinoma (HCC) - called "HCC surveillance" - offered to selected patients with chronic liver disease can reduce HCC-related mortality by facilitating earlier detection of HCC. The screening procedure consists of two tests: an ultrasound examination of the liver and a blood sample to measure alpha-fetoprotein. Patients who screen positive on either examination will be offered standard work-up for HCC, typically beginning with a CT-scan.Read full original descriptionShow less
Introducing HCC Surveillance in the Central Denmark Region
This study aims to investigate whether repeated 6-monthly screening for hepatocellular carcinoma (HCC) - called "HCC surveillance" - offered to selected patients with chronic liver disease can reduce HCC-related mortality by facilitating earlier detection of HCC. The screening procedure consists of two tests: an ultrasound examination of the liver and a blood sample to measure alpha-fetoprotein. Patients who screen positive on either examination will be offered standard work-up for HCC, typically beginning with a CT-scan.
In the study HCC surveillance will be offered to all patients with compensated non-viral cirrhosis residing in the Central Denmark Region, one of five administrative regions of Denmark. The study aims to determine the efficacy of HCC surveillance in reducing HCC-related mortality by comparing HCC-related mortality between the Central Denmark Region and the other four Danish regions, where HCC surveillance is not offered.
Inclusion: Cirrhosis; No history of chronic hepatitis B or C; Compensated cirrhosis defined as:; No recent variceal bleeding, no uncontrolled ascites, no clinically apparent hepatic encephalopathy, and Child-Pugh score ≤ 8; Age 40-79 years; Expected remaining life expectancy ≥ 1 year; Not already in follow-up after treatment for HCC; No clinical suspicion of HCC.
Exclusion: -.